The Non-Invasive Prenatal Testing Market Size is valued at USD 4.63 billion in 2023 and is predicted to reach USD 12.20 billion by the year 2031 at a 13.02 % CAGR during the forecast period for 2024-2031.
Non-invasive prenatal testing, often known as non-invasive prenatal screening, is a method for determining the likelihood that a fetus will have genetic abnormalities. This type of screening is risk-free and remarkably successful for Down syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, and other genetic conditions. By week 10 of pregnancy, little DNA fragments are detected in pregnant women's blood, which is frequently examined. Reduced fertility, high blood pressure, increased risk of miscarriage, stillbirths, and maternal mortality are just a few health problems that might arise as a mother ages. Maternal age can also increase the likelihood of genetic disorders in babies due to incorrect chromosomal division.
The demand for non-invasive prenatal diagnostics is therefore anticipated to increase as maternal age and the prevalence of chromosomal disorders both rise. The market's organic revenue growth is driven by an increase in the majority of chromosomal abnormalities and increased product usage in new applications. Additionally, improvements in existing tests' chemistry, usefulness, and bioinformatics analysis are anticipated to fuel market expansion. The market for non-invasive prenatal testing is driven by older women's more significant chance of having infants with Down syndrome.
Furthermore, the rise in children with chromosomal problems and advancements in diagnostic imaging technology drives the demand for non-invasive prenatal testing. The market for non-invasive prenatal diagnostics is anticipated to benefit from expanding insurance coverage for typical and low-risk pregnancies. However, the high cost of testing and provisional diagnostic tools restricts the market's growth. Two more issues that could impede the expansion of the global non-invasive prenatal testing market are the decreased per capita healthcare spending and the inadequate test reimbursement policies.
Competitive Landscape
Some of the Major Key Players in the Non-Invasive Prenatal Testing Market are:
- Genesis Genetics (CooperSurgical, Inc.)
- Natera, Inc.
- Eurofins LifeCodexx GmbH
- Illumina, Inc. (Verinata Health, Inc.)
- Centogene N.V.
- MedGenome Labs Ltd.
- Myriad Women’s Health, Inc. (Counsyl, Inc.)
- Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
- Qiagen
- Laboratory Corp. of America Holdings
- Progenity, Inc.
- Quest Diagnostics, Inc.
Market Segmentation
The non-invasive prenatal testing market is segmented by gestation period, pregnancy risk, method, technology, product, application, and end-user. Based on gestation period, the market is segmented into 0-12 weeks, 13-24 weeks, 25-36 weeks. The market is segmented by pregnancy risk into high & average risk, low risk. The market is segmented by method into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests. The market is segmented by technology into NGS, array technology, and others. The market is segmented by product into consumables & reagents, instruments. The market is segmented by application into trisomy, microdeletion syndrome, and other applications. The market is segmented by end-use into hospitals & clinics, diagnostic laboratories.
The cell-free DNA in maternal plasma tests category dominated the market. Various genetic tests are increasingly used in prenatal care to forecast the likelihood of genetic abnormalities. With the advent of whole-genome sequencing, technological developments have broadened the scope of testing and made it possible to identify many more chromosomal abnormalities, including microdeletions and sex-specific ones. However, the use of ultrasound detection as a complement to the NIPT test based on cell-free DNA results in a lower market share. However, more recent technological developments and 3D-4D imaging have enhanced the test's real-time monitoring, safety, and efficacy, which is further likely to fuel the segment's expansion.
The Trisomy Category Witnessed Growth At A Rapid Rate.
The trisomy category dominated the market in 2021 because of increased chromosomal abnormalities. The prevalence of genetic illnesses is high in India. According to much research, trisomy 21 (down syndrome), which has a high incidence rate of 1 in 800 births and results in the birth of 32,000 children with down syndrome every year, is discovered in 1 in 166 newborns nationwide. Whole genome sequencing tests are now available, and they can identify a wide range of additional chromosomal abnormalities, including microdeletions and sex-specific ones.
The North American Non-Invasive Prenatal Testing Market Holds A Significant Regional Revenue Share.
The North American non-invasive prenatal testing market is expected to register the highest market share in revenue shortly. This can be attributable to several factors, including the high preterm birth rate, the developed healthcare system, and the rising maternal mortality rate. The prevalence of chromosomal abnormalities is rising, as is public awareness of the advantages of non-invasive prenatal testing. These factors are driving the market's expansion. The demand for non-invasive prenatal testing is increasing significantly due to the top firms' increased focus on diversifying their product lines, boosting the market's growth. In addition, the development of new, technologically sophisticated tests has a significant impact on the market expansion in this region. In addition, Asia Pacific is projected to grow rapidly in the global non-invasive prenatal testing market because of the expanding healthcare systems in developing nations like China and India, among others. Rising public healthcare spending and increased knowledge of non-invasive prenatal testing will be projected to boost market expansion. Additionally, non-invasive prenatal testing developments and technology improvements are anticipated to drive the market's growth during the projection period.
Non-Invasive Prenatal Testing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 4.63 Bn |
|
Revenue Forecast In 2031 |
USD 12.20 Bn |
|
Growth Rate CAGR |
CAGR of 13.02% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Gestation Period, By Pregnancy Risk, By Method, By Technology, By Product, By Application, By End-User, and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Genesis Genetics (CooperSurgical, Inc.), Natera, Inc., Eurofins LifeCodexx GmbH, Illumina, Inc. (Verinata Health, Inc.), Centogene N.V., MedGenome Labs Ltd., Myriad Women’s Health, Inc. (Counsyl, Inc.), F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics), Qiagen, Laboratory Corp. of America Holdings, Progenity, Inc., Quest Diagnostics, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
